Key Highlights

• Shares traded at $10.29 pre-market, up 4.30% from the $9.87 prior close.

• PBGENE-HBV achieved pgRNA loss to undetectable in 100% of evaluable patients at the 0.4 mg/kg dose.

• Paired liver biopsies showed a 1-log and 1.5-log reduction in cccDNA at the 0.4 mg/kg dose.

• The data covered 25 patients across 59 administrations, with no dose-limiting toxicities reported.

• The company priced an underwritten offering expected to generate approximately $125 million in gross proceeds.

Precision BioSciences (NASDAQ:DTIL) shares were trading higher in pre-market activity on Friday, November 6, after the company released new and updated Phase 1 data for PBGENE-HBV, its in vivo gene editing program for chronic hepatitis B. The data will be presented in a late-breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2026 on Sunday, November 8. The lead investigator of the ELIMINATE-B study, Man Fung Yuen, will deliver the presentation.

The Durham, North Carolina-based company is a clinical stage gene editing company that uses its proprietary ARCUS platform to develop in vivo therapies. It describes PBGENE-HBV as the first and only in vivo gene editing therapy designed to eliminate covalently closed circular DNA (cccDNA), the root cause of chronic hepatitis B.

Viral Marker Loss and Liver Biopsy Results Anchor the Update

Among 12 evaluable patients with detectable pregenomic RNA (pgRNA) at baseline, 11 achieved undetectable pgRNA after treatment, including all six evaluable patients at 0.4 mg/kg. The company selected 0.4 mg/kg as the go-forward dose. In the first HBeAg-positive patient, pgRNA became undetectable after the second administration at 0.4 mg/kg, declining from 5,750 copies/mL at baseline. Paired liver biopsies from two patients at 0.4 mg/kg showed approximately 1-log and 1.5-log reductions in cccDNA.

All 24 evaluable patients experienced reductions in hepatitis B surface antigen (HBsAg), with maximal reductions approaching 94% at 0.4 mg/kg. The company said 0.4 mg/kg was better tolerated than 0.65 mg/kg, and no serious adverse events have been observed at the Phase 2 dose.

ELIMINATE-B2 Phase 2 Plans and Offering Terms

Precision is initiating the global ELIMINATE-B2 Phase 2 study, which will evaluate PBGENE-HBV as monotherapy and in combination with an antisense oligonucleotide. The company expects to begin dosing in the first quarter of 2027 and anticipates initial open-label data in the second half of 2027.

On November 5, the company announced pricing of an underwritten offering of 10,235,077 shares of common stock at $7.75 per share, plus pre-funded warrants for up to 5,893,964 shares. Gross proceeds are expected to be approximately $125 million, and the offering was expected to close on or about November 6, 2026. Proceeds will fund PBGENE-HBV and PBGENE-DMD research and working capital.

What Comes Next: Investor Webcast, Phase 2 Dosing and DMD Safety Review

The company will host an investor and KOL webcast on Monday, November 9, 2026, at 8:00 a.m. ET to present the AASLD Phase 1 data. Separately, an independent Data Safety Monitoring Board reviewed the first PBGENE-DMD patient in the FUNCTION-DMD study, reported no serious adverse events through week eight, and endorsed dosing additional patients in Part 1. The company plans safety and efficacy updates from that study throughout 2027.